OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:37 UTC. Every row links to its source record.

NT5C2 5'-nucleotidase, cytosolic II

ENSG00000076685 · protein coding · Open Targets profile

Broad specificity cytosolic 5'-nucleotidase that catalyzes the dephosphorylation of 6-hydroxypurine nucleoside 5'-monophosphates (PubMed:10092873, PubMed:12907246, PubMed:1659319, PubMed:9371705). In addition, possesses a phosphotransferase activity by which it can transfer a phosphate from a donor nucleoside monophosphate to an acceptor nucleoside, preferably inosine, deoxyinosine and guanosine (PubMed:1659319, PubMed:9371705). Has the highest activities for IMP and GMP followed by dIMP, dGMP and XMP (PubMed:10092873, PubMed:12907246, PubMed:1659319, PubMed:9371705). Could also catalyze the transfer of phosphates from pyrimidine monophosphates but with lower efficiency (PubMed:1659319, PubMed:9371705). Through these activities regulates the purine nucleoside/nucleotide pools within the cell (PubMed:10092873, PubMed:12907246, PubMed:1659319, PubMed:9371705). {ECO:0000269|PubMed:10092873, ECO:0000269|PubMed:12907246, ECO:0000269|PubMed:1659319, ECO:0000269|PubMed:9371705}.

In 15 of 15 cancers, the evidence for NT5C2 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751T-cell acute lymphoblastic leukemiaT-cell acute lymphoblastic leukemiaT-cell acute lymphoblastic leukemia: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61B-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemia: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61acute lymphoblastic leukemiaacute lymphoblastic leukemiaacute lymphoblastic leukemia: somatic 0.46acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.46non-small cell lung carcinomanon-small cell lung carcinomanon-small cell lung carcinoma: somatic 0.46breast carcinomabreast carcinomabreast carcinoma: somatic 0.46myelodysplastic syndromemyelodysplastic syndromemyelodysplastic syndrome: somatic 0.46

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand, Med-Quality Pocket
PROTAC
Database Ubiquitination, Half-life Data

gnomAD loss of function constraint: o/e 0.7620400190353394 (upper bound 0.9483000040054321). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of NT5C2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of NT5C2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.